Literature DB >> 21552147

ASPS-1, a novel cell line manifesting key features of alveolar soft part sarcoma.

Susan Kenney1, David T Vistica, Luke H Stockwin, Sandra Burkett, Melinda G Hollingshead, Suzanne D Borgel, Donna O Butcher, David S Schrump, Robert H Shoemaker.   

Abstract

In vitro growth of alveolar soft part sarcoma (ASPS) and establishment of an ASPS cell line, ASPS-1, are described in this study. Using a recently developed xenograft model of ASPS derived from a lymph node metastasis, organoid nests consisting of 15 to 25 ASPS cells were isolated from ASPS xenograft tumors by capture on 70 μm filters and plated in vitro. After attachment to the substratum, these nests deposited small aggregates of ASPS cells. These cells grew slowly and were expanded over a period of 3 years and have maintained characteristics consistent with those of both the original ASPS tumor from the patient and the xenograft tumor including (1) presence of the alveolar soft part locus-transcription factor E3 type 1 fusion transcript and nuclear expression of the alveolar soft part locus-transcription factor E3 type 1 fusion protein; (2) maintenance of the t(X;17)(p11;q25) translocation characteristic of ASPS; and (3) expression of upregulated ASPS transcripts involved in angiogenesis (ANGPTL2, HIF-1-α, MDK, c-MET, VEGF, and TIMP-2), cell proliferation (PRL, PCSK1), metastasis (ADAM9), as well as the transcription factor BHLHB3 and the muscle-specific transcripts TRIM63 and ITGβ1BP3. This ASPS cell line forms colonies in soft agar and retains the ability to produce highly vascularized ASPS tumors in NOD.SCID/NCr mice. Immunohistochemistry of selected ASPS markers on these tumors indicated similarity to those of the original patient tumor as well as to the xenografted ASPS tumor. We anticipate that this ASPS cell line will accelerate investigations into the biology of ASPS including identification of new therapeutic approaches for treatment of this slow growing soft tissue sarcoma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21552147      PMCID: PMC7518051          DOI: 10.1097/MPH.0b013e3182002f9f

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  30 in total

1.  Alveolar soft-part sarcoma: further evidence by FISH for the involvement of chromosome band 17q25.

Authors:  P Heimann; C Devalck; C Debusscher; E Sariban; E Vamos
Journal:  Genes Chromosomes Cancer       Date:  1998-10       Impact factor: 5.006

2.  Validation of potential therapeutic targets in alveolar soft part sarcoma: an immunohistochemical study utilizing tissue microarray.

Authors:  Alexander J Lazar; Guy Lahat; Sarah E Myers; Kerrington D Smith; Changye Zou; Wei-Lien Wang; Dolores Lopez-Terrada; Dina Lev
Journal:  Histopathology       Date:  2009-12       Impact factor: 5.087

Review 3.  Alveolar soft-part sarcoma: a review and update.

Authors:  A L Folpe; A T Deyrup
Journal:  J Clin Pathol       Date:  2006-11       Impact factor: 3.411

Review 4.  The potential anti-tumorigenic and anti-metastatic side of the proprotein convertases inhibitors.

Authors:  Rachid Lahlil; Fabien Calvo; Abdel-Majid Khatib
Journal:  Recent Pat Anticancer Drug Discov       Date:  2009-01       Impact factor: 4.169

5.  Midkine is regulated by hypoxia and causes pulmonary vascular remodeling.

Authors:  Paul R Reynolds; Michael L Mucenski; Timothy D Le Cras; William C Nichols; Jeffrey A Whitsett
Journal:  J Biol Chem       Date:  2004-06-14       Impact factor: 5.157

6.  Angiogenesis-promoting gene patterns in alveolar soft part sarcoma.

Authors:  Alexander J F Lazar; Parimal Das; Daniel Tuvin; Borys Korchin; Quansheng Zhu; Zeming Jin; Carla L Warneke; Peter S Zhang; Vivian Hernandez; Dolores Lopez-Terrada; Peter W Pisters; Raphael E Pollock; Dina Lev
Journal:  Clin Cancer Res       Date:  2007-12-15       Impact factor: 12.531

7.  Therapeutic vulnerability of an in vivo model of alveolar soft part sarcoma (ASPS) to antiangiogenic therapy.

Authors:  David T Vistica; Melinda Hollingshead; Suzanne D Borgel; Susan Kenney; Luke H Stockwin; Mark Raffeld; David S Schrump; Sandra Burkett; Gary Stone; Donna O Butcher; Robert H Shoemaker
Journal:  J Pediatr Hematol Oncol       Date:  2009-08       Impact factor: 1.289

Review 8.  Proteolytic processing mechanisms in the biosynthesis of neuroendocrine peptides: the subtilisin-like proprotein convertases.

Authors:  Y Rouillé; S J Duguay; K Lund; M Furuta; Q Gong; G Lipkind; A A Oliva; S J Chan; D F Steiner
Journal:  Front Neuroendocrinol       Date:  1995-10       Impact factor: 8.606

9.  Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model.

Authors:  J J O'Leary; R L Shapiro; C J Ren; N Chuang; H W Cohen; M Potmesil
Journal:  Clin Cancer Res       Date:  1999-01       Impact factor: 12.531

10.  A novel muscle-specific beta 1 integrin binding protein (MIBP) that modulates myogenic differentiation.

Authors:  J Li; R Mayne; C Wu
Journal:  J Cell Biol       Date:  1999-12-27       Impact factor: 10.539

View more
  9 in total

1.  Modeling alveolar soft part sarcomagenesis in the mouse: a role for lactate in the tumor microenvironment.

Authors:  Matthew L Goodwin; Huifeng Jin; Krystal Straessler; Kyllie Smith-Fry; Ju-Fen Zhu; Michael J Monument; Allie Grossmann; R Lor Randall; Mario R Capecchi; Kevin B Jones
Journal:  Cancer Cell       Date:  2014-11-26       Impact factor: 31.743

2.  Establishment and characterization of NCC-ASPS1-C1: a novel patient-derived cell line of alveolar soft-part sarcoma.

Authors:  Yuki Yoshimatsu; Rei Noguchi; Ryuto Tsuchiya; Akane Sei; Jun Sugaya; Suguru Fukushima; Akihiko Yoshida; Akira Kawai; Tadashi Kondo
Journal:  Hum Cell       Date:  2020-07-10       Impact factor: 4.174

3.  A pan-cancer modular regulatory network analysis to identify common and cancer-specific network components.

Authors:  Sara A Knaack; Alireza Fotuhi Siahpirani; Sushmita Roy
Journal:  Cancer Inform       Date:  2014-10-28

4.  Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma.

Authors:  Robert Nakayama; Yi-Xiang Zhang; Jeffrey T Czaplinski; Alex J Anatone; Ewa T Sicinska; Jonathan A Fletcher; George D Demetri; Andrew J Wagner
Journal:  Oncotarget       Date:  2016-03-29

5.  Cabozantinib and dastinib exert anti-tumor activity in alveolar soft part sarcoma.

Authors:  Kenta Mukaihara; Yu Tanabe; Daisuke Kubota; Keisuke Akaike; Takuo Hayashi; Kaoru Mogushi; Masaki Hosoya; Shingo Sato; Eisuke Kobayashi; Taketo Okubo; Youngji Kim; Shinji Kohsaka; Tsuyoshi Saito; Kazuo Kaneko; Yoshiyuki Suehara
Journal:  PLoS One       Date:  2017-09-25       Impact factor: 3.240

6.  Antibody-independent capture of circulating tumor cells of non-epithelial origin with the ApoStream® system.

Authors:  Priya Balasubramanian; Robert J Kinders; Shivaani Kummar; Vishal Gupta; David Hasegawa; Anoop Menachery; Scott M Lawrence; Lihua Wang; Katherine Ferry-Galow; Darren Davis; Ralph E Parchment; Joseph E Tomaszewski; James H Doroshow
Journal:  PLoS One       Date:  2017-04-12       Impact factor: 3.240

7.  Alveolar soft-part sarcoma (ASPS) resembles a mesenchymal stromal progenitor: evidence from meta-analysis of transcriptomic data.

Authors:  Luke H Stockwin
Journal:  PeerJ       Date:  2020-06-19       Impact factor: 2.984

8.  Bioinformatic analysis of patient-derived ASPS gene expressions and ASPL-TFE3 fusion transcript levels identify potential therapeutic targets.

Authors:  David G Covell; Anders Wallqvist; Susan Kenney; David T Vistica
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

9.  A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma.

Authors:  Miso Kim; Tae Min Kim; Bhumsuk Keam; Yu Jung Kim; Jin Chul Paeng; Kyung Chul Moon; Dong-Wan Kim; Dae Seog Heo
Journal:  Oncologist       Date:  2018-09-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.